CRISPR TherapeuticsvsJohnson & Johnson

CRSP and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CRSP

CRISPR Therapeutics AG

$39.10

Value $3.8B

+0.44%
CRSP's page

CRISPR Therapeutics (CRSP) has a market value of $3.8B and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, CRSP moved -22.9% and JNJ +36.6%. Dividend yield: CRSP none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CRSP$3.8B

    JNJ$652B

    JNJ is 174 times CRSP

  • Revenue, 12 months

    CRSP$25M

    JNJ$99.3B

    JNJ is 3,946 times CRSP

  • Net income, 12 months

    CRSP-$456M

    JNJ$16.1B

  • Operating margin

    CRSP-2,114.8%

    JNJ–

  • ROIC

    CRSP-19.4%

    JNJ12.4%

    31.8 points apart

  • P/E

    CRSP–

    JNJ40.5

  • Dividend yield

    CRSP0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    CRSP-52.6%

    JNJ+90.9%

    143.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CRSP-52.6%

JNJ+90.9%

5010015020020222023202420252026
Returns by period
PeriodCRSPWith dividendsJNJWith dividends
1 year since November 19, 2025-22.9%Price -22.9%+36.6%Price +33.6%
3 years since November 20, 2023-45.8%-18.5% a yearPrice -45.8%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-52.6%-13.9% a yearPrice -52.6%+90.9%+13.8% a yearPrice +66.0%
10 years since November 21, 2016+88.0%+6.5% a yearPrice +88.0%+206.5%+11.9% a yearPrice +135.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CRSPCRISPR TherapeuticsJNJJohnson & Johnson

Valuation

CRSPJNJ
Valuation
Price$39.10$270.47
Market value$3.8B$652B
Enterprise value (EV)$2.1B$679B
P/E–40.5
P/E, 5-year median–21.9
P/B2.38.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

CRSPJNJ
Results and growth
Revenue, 12 months$25M$99.3B
Net income, 12 months-$456M$16.1B
Free cash flow, 12 months-$377M$20.6B
Earnings per share, 12 months-$4.72$6.59
Revenue growth, year on year-90.6%6.1%
Revenue growth a year, past+37.3%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CRSPJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-2,114.8%–
Net margin-1,812.1%16.2%
ROIC-19.4%12.4%
ROE-25.2%19.7%

Balance sheet

CRSPJNJ
Balance sheet
Cash$2.3B$17.2B
Total debt$780M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

CRSPJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CRSP or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, CRISPR Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 173.7 times CRISPR Therapeutics ($3.8B), at today's prices.

How did CRSP and JNJ stock do over the last 10 years?

Since November 21, 2016, CRSP's price moved +88.0% and JNJ's +135.2%. With dividends: CRSP +88.0% (+6.5% a year), JNJ +206.5% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, CRSP or JNJ?

The dividend yield at today's price is none for CRISPR Therapeutics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, CRISPR Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -1,812.1% for CRISPR Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -2,114.8% and –. Revenue was $25M and $99.3B.

Which is the better investment, CRISPR Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.